P.69NEO1 and NEO-EXT studies: exploratory efficacy of repeat avalglucosidase alfa dosing for up to 5 years in participants with late-onset Pompe disease (LOPD)

MLA

Sabrina Sacconi, et al. “P.69NEO1 and NEO-EXT Studies: Exploratory Efficacy of Repeat Avalglucosidase Alfa Dosing for up to 5 Years in Participants with Late-Onset Pompe Disease (LOPD).” Neuromuscular Disorders, vol. 29, Oct. 2019, pp. S60–61. EBSCOhost, https://doi.org/10.1016/j.nmd.2019.06.098.

APA

Sabrina Sacconi, O. Goker-Alpan, Barry J. Byrne, Shafeeq Ladha, A.T. van der Ploeg, Richard J. Barohn, Patricia A. Fraser, Loren Pena, K. An Haack, Priya S. Kishnani, Benedikt Schoser, Mazen M. Dimachkie, V. Straub, Jaya Trivedi, Peter Young, J. Vissing, Karl-Eugene Mengel, P. Van Damme, Kejian Liu, & P. Laforêt. (2019). P.69NEO1 and NEO-EXT studies: exploratory efficacy of repeat avalglucosidase alfa dosing for up to 5 years in participants with late-onset Pompe disease (LOPD). Neuromuscular Disorders, 29, S60–S61. https://doi.org/10.1016/j.nmd.2019.06.098

Chicago

Sabrina Sacconi, O. Goker-Alpan, Barry J. Byrne, Shafeeq Ladha, A.T. van der Ploeg, Richard J. Barohn, Patricia A. Fraser, et al. 2019. “P.69NEO1 and NEO-EXT Studies: Exploratory Efficacy of Repeat Avalglucosidase Alfa Dosing for up to 5 Years in Participants with Late-Onset Pompe Disease (LOPD).” Neuromuscular Disorders 29 (October): S60–61. doi:10.1016/j.nmd.2019.06.098.